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The general transcription factor IIE (TFIIE) is essential for transcription initiation by RNA polymerase II (RNA pol II) via direct interaction
with the basal transcription/DNA repair factor IIH (TFIIH). TFIIH harbors mutations in two rare genetic disorders, the cancer-prone
xeroderma pigmentosum (XP) and the cancer-free, multisystem developmental disorder trichothiodystrophy (TTD). The phenotypic
complexity resulting from mutations affecting TFIIH has been attributed to the nucleotide excision repair (NER) defect as well as to
impaired transcription. Here, we report two unrelated children showing clinical features typical of TTD who harbor different homozy-
gous missense mutations in GTF2E2 (c.448G>C [p.Ala150Pro] and c.559G>T [p.Asp187Tyr]) encoding the beta subunit of transcription
factor IIE (TFIIEb). Repair of ultraviolet-induced DNA damage was normal in the GTF2E2 mutated cells, indicating that TFIIE was not
involved in NER. We found decreased protein levels of the two TFIIE subunits (TFIIEa and TFIIEb) as well as decreased phosphorylation
of TFIIEa in cells from both children. Interestingly, decreased phosphorylation of TFIIEa was also seen in TTD cells with mutations in
ERCC2, which encodes the XPD subunit of TFIIH, but not in XP cells with ERCC2mutations. Our findings support the theory that TTD is
caused by transcriptional impairments that are distinct from the NER disorder XP.Introduction
The basal transcription factor IIH (TFIIH) has essential
functions in RNA pol I and RNA pol II transcription, as
well as nucleotide excision repair (NER) of ultraviolet
(UV)-induced DNA lesions. TFIIH is a multi-protein com-
plex comprised of a 7-subunit core (XPB, XPD, p62, p52,
p44, p34, and TTDA) and a 3-subunit cyclin activating
kinase (CAK) complex formed by CDK7, MAT1, and
cyclin H.1 In RNA pol I transcription, the TFIIH ATPase
activity of XPB is required for proper transcription of
ribosomal DNA.2,3 In RNA pol II transcription, the helicase
activity of TFIIH subunit XPB and the ATPase activity of
XPD are involved in promoter opening. The TFIIH kinase
activity of CDK7 is required for RNA pol II phosphoryla-
tion at the C-terminal domain (CTD). In NER, the helicase
activity of XPD and the ATPase activity of XPB open the
DNA strand around a UV-induced lesion in order to permit
incision and repair of the damaged DNA strand.4
Mutations in ERCC2 (OMIM: 126340) and ERCC3
(OMIM: 133510), encoding the TFIIH subunits XPD and
XPB, respectively, cause the rare autosomal-recessive dis-
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The Amtrophy (TTD) (OMIM: 610651, 278730, 608780).5 All the
mutations found in TTD-affected individuals result in
reduced steady-state levels of the entire TFIIH complex (Ta-
ble S1) and impaired functioning in repair and transcrip-
tion (reviewed in Stefanini et al.6). Although individuals
with XP have a 10,000-fold increased risk of skin cancer,
individuals with TTD have normal skin cancer risk even
though they might present with cutaneous photosensi-
tivity. In addition, individuals with TTD show deve-
lopmental defects including neurological and hair
abnormalities (Figure S1). Most of these individuals with
XP or TTD are compound heterozygous and both alleles
might contribute to the phenotype.4,7–9 This complex
phenotypic variability is associated with different muta-
tion(s) in ERCC2 or ERCC3 that, in addition to interfering
with the role of TFIIH in repair, differentially affect the
multiple functions of TFIIH in transcription, including
basal and activated transcription. Features of XP are
thought to be associated with ERCC2 and ERCC3 muta-
tions primarily affecting DNA repair,5,8 whereas ERCC2
and ERCC3mutations associated with TTD show transcrip-
tional alterations in addition to impaired NER4,9–11 (see
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In addition to the NER-defective form of TTD due to
mutations in genes encoding TFIIH subunits (OMIM:
601675), an additional TTD form (OMIM: 234050) charac-
terized by the absence of clinical and cellular photosensi-
tivity, normal response to UV light, and TFIIH steady-state
level has been reported. A small proportion of the
non-photosensitive TTD case subjects harbor mutations
in TTDN1 (trichothiodystrophy non-photosensitive 1
[MPLKIP]12–14 [OMIM: 609188]) whose product seems to
be involved in cell cycle progression15 although its precise
function still remains unknown. Recently, an X-linked
form of non-photosensitive TTD was found associated
with a nonsense mutation in RNF113A (ring finger protein
113A [OMIM: 300953]) in two Australian cousins.16 The
molecular function of RNF113A remains unknown.
Here we report two unrelated non-photosensitive chil-
dren with TTD from different parts of the world who
were studied by scientists from Europe and the US. The
affected children’s cells were NER proficient and did not
have mutations in any of the genes known to be associated
with TTD. In searching for TTD-associated genes that could
cause the TTD phenotype, the European group employed a
targeted approach by studying several basal transcription
factors that act in concert with TFIIH whereas the US group
applied whole-exome sequencing technology. These
different approaches led to the identification of two homo-
zygous missense mutations in the same gene, GTF2E2
(OMIM: 189964), encoding the beta subunit of the basal
transcription factor II E (TFIIEb). This transcription factor
is essential for the assembly and stabilization of the RNA
pol II pre-initiation complex (PIC) at the transcription start
site.17 TFIIE enters the PIC after RNA pol II, recruits TFIIH
to the PIC, stimulates RNA pol II CTD phosphorylation
by the CDK7 subunit of TFIIH, and regulates the helicase
activity of XPB to catalyze the open complex formation,
leading to promoter clearance.18–20 The two individuals
with mutations in GTF2E2 studied here have normal
NER but reduced cellular levels of both subunits of the
TFIIE complex (TFIIEa and TFIIEb). In addition, the patho-
logical alterations in TFIIEb resulted in decreased amounts
of the overall TFIIE complex and of phosphorylated
TFIIEa. Reduced levels of phosphorylated TFIIEa were
also seen in TTD cells with ERCC2 (XPD) mutations but
not in XP cells with mutations in ERCC2.Material and Methods
Affected Individuals, Cell Culture, UV Sensitivity
Testing, and Transfection
The affected children were studied under protocols approved by
the Institutional Review Boards at the US NIH and Vrije Universi-
teit Brussel. Written informed consent was obtained from the
parents of the children. Normal, XP, and TTD primary human
skin fibroblasts from the Human Genetic Mutant Cell Repository
and lymphoblastoid cell lines from Fisher BioServices (NCI Freder-
ick Central Repository) or established in Pavia, Italy, were cultured
as described.21 The study was performed on primary fibroblasts of628 The American Journal of Human Genetics 98, 627–642, April 7, 2the affected individuals TTD28PV and TTD379BE and the parents
of TTD379BE and on lymphoblastoid cells of TTD28PV, the par-
ents and healthy sister of TTD28PV, and on a healthy donor,
C6PV. Investigations on TFIIEa were extended to primary fibro-
blasts of six TTD- and six XP-affected individuals with mutations
in ERCC2 (XPD) (Table S1). Normal primary fibroblasts from
four genetically unrelated healthy donors (C3PV, C377RM,
C1609RM, C16354BE) and from the phenotypically normal par-
ents of TTD379BE were analyzed in parallel. For proliferating
and non-proliferating cultures, 3 3 105 fibroblasts were seeded
in 6-cm Petri dishes and cultured for 3 and 10 days, respectively,
before processing. Cell survival after UV irradiation was measured
using CellTiter96 Non-Radioactive Cell Proliferation Assay (Prom-
ega). After UV host cell reactivation, DNA repair assays were
performed by transfection of 1 mg of UVC-irradiated (1,000 or
500 J/m2) or non-irradiated luciferase expression vector into
2.53 105 fibroblasts using Lipofectamine 2000 (Life Technologies)
according to the vendor’s protocol. Luciferase activity was
measured as described.22 Transient expression of recombinant
TFIIEaFlag was obtained by transfecting 2 mg of pMP2-TFIIEaFlag
plasmid into 1 3 106 C3PV primary fibroblasts by Amaxa Nucleo-
fector technology (Lonza). Cells were processed 48 hr after trans-
fection. Evaluation of unscheduled DNA synthesis (UDS) and
recovery of RNA synthesis (RRS) were carried out according to
routine procedures.23–25DNA Isolation and Sequencing
We isolated DNA from blood of TTD-affected individuals who had
been examined at the NIH Clinical Center under protocols
approved by the National Cancer Institute Institutional Review
Board. Genomic DNA from blood or cell lines was isolated via
DNeasy Blood & Tissue Kit (QIAGEN), purified via Genomic
DNA Clean & Concentrator (Zymo Research), and used for
whole-exome sequencing or Sanger sequencing via GTF2E2
reverse primer GTF2E2-R1 (Table S2) to confirm the mutation
detected by whole-exome sequencing.
In TTD28PV primary fibroblasts, the complete coding region of
GTF2E2 was analyzed by sequencing of PCR-amplified cDNA, and
the mutation was investigated in the relevant genomic DNA re-
gion of the family members. Additional TTD-affected subjects
were screened for mutations in GTF2E2 and GTF2E1 by directed
sequencing of either the cDNA or genomic DNA using PCR and
sequencing primers (Table S2).Whole-Exome Sequencing and Data Analysis
Exonic DNA was captured using Agilent SureSelect Human All
Exon V5þUTRs target enrichment kit (Agilent Technologies),
which targets 75 megabases (21,522 genes and 359,555 exons).
Exome libraries were prepared according to manufacturers’ recom-
mended protocols. Sequencing was performed via an Illumina
HiSeq2000 (Illumina), and the sequencing was run as 2 3 101
base pairs with TruSeq V3-HS reagents. The HiSeq Real Time
Analysis (RTA 1.12.4.2) was used for processing image files, and
the Illumina CASAVA_v1.8.2 was used to demultiplex and convert
binary base calls and qualities to fastq format. The TTD379BE sam-
ple had 127 million reads and more than 93% of the bases had
quality values of Q30 and above. The sequencing reads were
trimmed of adapters and of low-quality bases using Trimmomatic
and were aligned to human hg19 reference genome (GRCh37/
UCSC hg19) using the short read alignment component in
Burrows-Wheeler Aligner BWA v.0.7.26 The mean alignment016
percentage was 98.9% mapped to reference genome, and 68% of
the mapped reads were on target within the capture regions. The
mean depth of coverage was 1063 with more than 99.7% of the
target regions covered at least 103, and 94.54% target regions
were covered at least 303 sequencing depth.
The Genome Analysis Toolkit (GATK_v2.5, developed at Broad
Institute) was used to perform variant discovery and genotyping.
SNPs and indels were called according to the GATK’s Best Practices.
In brief, the Mapped BAM files were modified to add read groups,
marked for duplicates, and sorted with Picard software. The align-
ments were locally realigned around candidate indels and align-
ment base quality scores were recalibrated. After the mapped
read pre-processing, the variants were initially called with the Uni-
fied Genotyper. The raw SNPs and indels were further processed
via the GATK’s variant quality score recalibration (VQSR) work-
flow. For further analysis, we selected variants that were within
the target regions covered by the SureSelect All Exon V5þURT
kit. In addition, we used a Mendelian inheritance model and per-
formed trio analysis to assess the Mendelian error rates. The anal-
ysis-ready SNPs and INDELs were then annotated for functional
significance with Variant Effect Predictor (VEP, Ensembl) and
ANNOVAR software. The annotated non-synonymous variants
were further filtered based on SIFT27 and PolyPhen228 and cla-
ssified as ‘‘not benign’’ or ‘‘not tolerated,’’ respectively. We also
applied variant annotation and interpretation analyses generated
through the use of QIAGEN’s Ingenuity Variant Analysis software
for validation and further evaluation of the prioritized variants.
Quantitative Real-Time PCR
Total RNA was extracted using RNAqueous extraction kit (Life
Technologies) or the RNeasy Mini Kit (QIAGEN). Transcript levels
of GTF2E2 and GAPDH (for normalization) were measured on a
Biorad CFX96 or a LightCycler 480 (Roche). Primer sequences
are in Table S2.
RNA Interference
GTF2E2 or CDK7 silencing was performed as previously
described.9 In brief, 8 3 105 primary fibroblasts were transfected
with 360 mmol control (AllStar negative control, QIAGEN Sci-
ences), GTF2E2 or CDK7 siRNA (FlexiTube siRNA, QIAGEN
Sciences) using the HiPerfect Transfection Reagent (QIAGEN Sci-
ences) and incubated at 37C for different time points. Transfected
cells were processed for qPCR and immunoblot analysis.
Phosphoprotein Enrichment
Phosphoprotein-enriched fractions were obtained using the Pro-Q
Diamond Phosphoprotein Enrichment Kit (Molecular Probes by
Life Technologies). In brief, 83 105 primary fibroblasts were lysed
in 500 mL of supplied lysis buffer and the clarified supernatant was
loaded on Pro-Q Diamond columns. Phosphorylated and unphos-
phorylated protein enriched fractions were eluted in 5 mL and
1.25 mL of elution buffer, respectively, and thereafter concen-
trated to a volume of 50 mL by using Amicon Ultra-4 Columns
(Millipore). Concentrated fractions were diluted in Laemmli buffer
and analyzed by immunoblotting.
Phosphatase Treatment
Protein dephosphorylation was carried out using calf intestinal
alkaline phosphatase (CIP). Primary fibroblasts were lysed in cul-
ture dishes via directly scraping in CIP buffer (100 mM NaCl,
50 mM Tris, 10 mM MgCl2, 1 mM dithiothreitol [pH 7.9]) sup-The Amplemented with EDTA-free Protease Inhibitor Cocktail (Roche
Diagnostic). Cell lysates were incubated at 37C for different
time points after addition of 3 U/mL CIP (Sigma Aldrich). Inhibi-
tion of CIP activity was obtained by adding 13 PhosSTOP
(Roche Diagnostic) to the cell lysates. After treatment,
samples were diluted in Laemmli buffer and analyzed by
immunoblotting.Immunoprecipitation
Immunoprecipitation was performed on HeLa cells or C3PV pri-
mary fibroblasts lysed in RIPA buffer (50 mM Tris [pH 7.4],
150 mM NaCl, 1% Triton, 0.25% Na-deoxycholate, 0.1% SDS) ac-
cording to standard protocols. Primary antibodies utilized were
anti-TFIIEa (2A1), anti-Flag (Sigma), and mouse IgG (Santa Cruz
cat# sc-2025; RRID: AB_737182).Protein Isolation, Immunoblotting, and
Immunofluorescence
Whole-cell lysates were prepared for immunoblotting as described
previously.22 TFIIH, TFIIE, TBP, TFIIB, and TTDN1 proteins were
analyzedby lysing cell pellets of primaryfibroblasts or lymphoblasts
in urea buffer (62.5 mM Tris [pH 6.8], 4 M urea, 2% SDS, 10% glyc-
erol, 0.005% bromophenol blue, 3% b-mercaptoethanol) as previ-
ously described.29,30 TFIIEa phosphorylation in primary fibroblasts
was investigated by direct lysis in culture dishes via scraping in
23 Laemmli buffer (125 mM Tris [pH 6.8], 4% SDS, 20% glycerol,
0.01% bromophenol blue, 6% b-mercaptoethanol) supplemented
with PhosSTOP (Roche Diagnostic), and proteins were separated
on 4%–20% gradient gels (Protean TGX, BioRad).31
For immunofluorescence analysis, cells were labeled with
different sizes of polystyrene beads (normal cells 0.99 mm, affected
subject cells 2.17 mm) as described before.32 Cells were grown on
microscope cover glass (Thermo Scientific) and UV irradiated
(254 nm, 100 J/m2) through a polycarbonate isopore membrane
(pore size, 5 mm; diameter, 25 mm; Millipore) as described33 or
left unirradiated. Immunofluorescence labeling and imaging was
performed as described.22
The following commercial primary antibodies were used for
immunoblotting at the indicated dilutions: mouse-anti-g-tubulin
(Sigma-Aldrich cat# T6557; RRID: AB_477584), 1:10,000; mouse-
anti XPA (Santa Cruz cat# sc-73272; RRID: AB_1131404), 1:100;
mouse-anti-GTF2E1 (Novus Biologicals cat# H00002960-B01;
RRID: AB_2279378), 1:100; rabbit-anti-GTF2E2 (Novus Biologicals
cat# NBP1-87931; RRID: AB_1102880), 1:150; rabbit-anti-XPB
(Santa Cruz cat# sc-293; RRID: AB_2262177), 1:150; rabbit-anti-
XPD (Santa Cruz cat# sc-20696; RRID: AB_2100152), 1:150; rab-
bit-anti XPC (Santa Cruz cat# sc-30156; RRID: AB_2241587),
1:200; rabbit anti-TTDN1 (Abcam cat# ab34309; RRID:
AB_870614), 1:500; mouse-anti-Pol II-Ser5 (Covance, cat# MMS-
134R; RRID: AB_10119940), 1:500; mouse anti-phosphoserine,
anti-phosphothreonine, and anti-phosphotyrosine (525288,
Detection kit, Calbiochem), 1:250. Mouse antibodies against the
TFIIH subunits CDK7 (2F8), p44 (1H5), p62 (3C9), and XPD
(2F6), the TFIIE subunits a (2A1) and b (1C2), TBP (3G3), TFIIB
(4A10), and RNA pol II (7C2) were a gift from J.M. Egly and were
all diluted 1:2,000.Statistical Analysis
Statistical analysis was performed with a two-tailed Student’s
t test. Fisher F-ratio at a probability level of 0.05 was used toerican Journal of Human Genetics 98, 627–642, April 7, 2016 629
Figure 1. TTD-Affected Children TTD379BE and TTD28PV
(A) TTD379BE, a 10-year-old boy from India with mild micrognathia, low-set ears, and short hair.
(B) Hair of affected child TTD379BE showing alternating dark and light ‘‘tiger tail’’ banding (arrows) with polarizedmicroscopy typical of
TTD.61 Hair shafts vary in diameter (*).
(C) Pedigree of TTD379BE (IV-1). His clinically normal parents (III-3 and III-4) are first cousins.
(D) Hair of 16-year-old affected girl, TTD28PV, showing tiger tail banding with polarized microscopy (arrows). The hair shafts also have
dark transverse bands that indicate sites of hair fractures (trichoschisis) (arrowhead).
(E) Pedigree of TTD28PV (V-1). Her parents (IV-1 and IV-2) are consanguineous.compare variances among the analyzed groups. *p < 0.05, **p <
0.005, ***p < 0.0005.
Results
Clinical Descriptions of Affected Children
TTD379BE
TTD379BE (IV-1 in Figure 1C), a 10-year-old Asian boy, was
diagnosed with TTD at age 1 year (Table 1 and Figure S1).
He was born in India at term with low birth weight
(2.4 kg; 10th percentile). As with other individuals with
TTD,13,34,35 the pregnancy was complicated by mild intra-
uterine growth retardation. His skin was normal with no
collodion membrane and no sun sensitivity but he was
noted to have very dry skin and sparse and slow-growing
hair. His gross motor development was delayed. Esotropia
was surgically corrected at age 5 years. He had cognitive de-
lays noted at age 3 years. He is described as a very happy,
overly friendly child.630 The American Journal of Human Genetics 98, 627–642, April 7, 2At age 10 years, he appeared younger than his chrono-
logic age (Figure 1A). His height, weight, and head
circumference were <3rd percentile. His scalp hair was
short, thick, and brittle. His hair showed typical alter-
nating dark and light ‘‘tiger tail’’ banding on polarized mi-
croscopy (Figure 1B). He did not have the large number of
freckle-like pigmented lesions in sun-exposed sites that
are present in individuals with xeroderma pigmentosum
(XP)5 (Table 1 and Figure S1). There was thick, coarse ich-
thyosiform scaling. There was no evidence of lenticular
opacities. Neurological evaluation showed abnormal
long tract signs and cerebellar dysfunction. His deep
tendon reflexes were 1–2þ. He had marked cognitive de-
lays including a speech articulation disorder with features
of attention deficit disorder. Formal IQ testing was not
performed. He had slight sensorineural hearing loss bilat-
erally. His parents are first cousins (III-3 and III-4 in
Figure 1C). Both parents and his brother (IV-2 in
Figure 1C) are clinically normal.016


















Dry skin yes yes yes yes no
Ichthyosis yes yes yes no no
Short, brittle hair yes yes yes no no
Hair tiger-tail banding yes yes yes no no
Short stature yes yes yes no no
Microcephaly yes yes yes no no
Developmental delay yes yes yes yes/no no
Happy personality yes yes yes no no
Acute burning on minimal
sun exposure
yes no no yes no
Recurrent infections yes no no no no
Increased freckle-like pigmentation no no no yes no
Skin cancer no no no yes no
Clinical Lab Studies
Low RBC mean corpuscular volume yes yes yes no no
Elevated Hemoglobin A2 yes yes yes no no
Dilated brain ventricles (CT or MRI) no no no yes no
aTerms in all capital letters indicate greater contribution to the phenotype.In laboratory tests, the MCV was reduced to 64.5
(normal 74.4–86.1) and his hemoglobin electrophoresis
showed elevated Hb A2 (Table 1 and Figure S1) as described
in other individuals with TTD.36 He had normal bone age
and no evidence of osteosclerosis, osteopenia, or hip ab-
normality as seen in some individuals with TTD.13,34 How-
ever, he had probable craniosynostosis of coronal sutures.
CT exam showed a morphologically normal brain with
no gross atrophy or calcifications. There was decreased
attenuation throughout the white matter, possibly repre-
senting a leukoencephalopathy.
TTD28PV
TTD28PV (V-1 in Figure 1E), a 16-year-old Moroccan girl,
weighed 3,110 g at 38.5 weeks gestation (Table 1 and
Figure S1) with an uncomplicated pregnancy. There was
no notion of a collodion membrane and she was not sun
sensitive. She had a patent ductus arteriosus at birth that
was closed by catheterization. She had brittle hair with
tiger-tail banding under polarized microscopy (Figure 1D)
and lamellar ichthyosis of her skin. She could sit at
1 year, walk independently at 35 months, and spoke
1 word at 33 months. She suffered from chronic rhin-
osinusitis but did not need hospitalization for infections
or other problems. She wears glasses (0.5 D). She is
very friendly, always laughing with good social interaction.The AmAt 16 years her height and weight were<<3rd percentile.
She had bilateral pes cavus with Babinski in extension. She
had an IQ of 40 and was in special education classes for
children with moderate intellectual disability. She had
growth hormone deficiency and has been treated with
growth hormone with good response. Hb A2 and Hb F
were elevated and MCV was low, indicating microcytosis
as seen in other TTD-affected individuals (Figure S1).13,34
She has mild hearing loss. MRI of the brain at 2 years
and at 10 years was normal. X-ray of the pelvis at
21 months showed bilateral coxa valga and delayed bone
age (10 years at 13 years of age).
The parents (IV-1 and IV-2 in Figure 1E) are from
Morocco and are distantly related although their precise
ancestry is not known. They have five other children
(V-2 to V-6 in Figure 1E) who are phenotypically normal
(Figure 1E). For further details, see Supplemental Note.
Normal UV Damage Repair Ability in TTD379BE and
TTD28PV Cells
TTD cells with mutations in ERCC3 (XPB), ERCC2 (XPD),
or GTF2H5 (TTDA [OMIM: 608780]) are defective in the
removal of UV-induced DNA damage by NER.6,29,37,38 Un-
like the other TTD cells (Table 2 and Figure S1), cells from
both TTD379BE and TTD28PV have normal post-UV DNAerican Journal of Human Genetics 98, 627–642, April 7, 2016 631


















Reduced post-UV cell survival
and host cell reactivation
yes no no yes no
Reduced repair of cyclobutane
pyrimidine dimer photoproducts
yes no no yes no
Reduced XPB and XPD proteins yes no no yes no
Transcription
Reduced TFIIEb protein no yes yes no no
Reduced TFIIEa protein no yes yes no no
Reduced phosphorylated TFIIEa
protein in confluent cells
yes yes yes no no
aTerms in all capital letters indicate greater contribution to the phenotype.repair as shown by their normal sensitivity to UV irradia-
tion (Figure 2A), host cell reactivation (repair of a UV-irra-
diated luciferase vector) that was not lower than normal
(Figures 2B and S2), and normal removal of 6-4 photoprod-
ucts (Figure 2C) and cyclobutane pyrimidine dimers
(Figure 2D).We also found normal recruitment of NER pro-
teins (XPC, XPA, XPB, and XPD) to UV-induced localized
DNA damage (Figure 2E). In addition, in primary fibro-
blasts from TTD28PV, we analyzed the efficiency of NER
by evaluating unscheduled DNA synthesis (UDS) and re-
covery of RNA synthesis (RRS) after UV irradiation
(Figure S2). After exposure to 10 and 20 J/m2 UV radiation,
the level of UDS corresponded to 95% of that in normal
cells. As with the normal donor, 24 hr after irradiation
with 20 J/m2, the case subject’s cells recovered RNA synthe-
sis to the level in un-irradiated cells. Therefore, both clin-
ical and cellular studies lead to the classification of both
TTD28PV and TTD379BE children in the non-photosensi-
tive group of TTD. However, no alterations were found in
MPLKIP (TTDN1 [OMIM: 609188]) that accounts for about
10%–20% of the non-photosensitive TTD-affected case
subjects.
Reduced Levels of TFIIE Complex in TTD28PV and
TTD379BE Cells
The link between TTD and transcription alterations
prompted us to investigate the cellular levels of several
RNA pol II-basal transcription factors. Normal amounts
of TBP, TFIIB, TFIIH complex, as well as TTDN1 were
found in TTD379BE and TTD28PV cells (Figure 3A). In
contrast, immunoblotting studies revealed drastic reduc-
tions in the levels of both a and b subunits of TFIIE
complex in primary fibroblasts from TTD28PV and
TTD379BE (Figure 3A) and in lymphoblasts of TTD28PV
(Figure 3B) compared to TTD28PV’s healthy relatives632 The American Journal of Human Genetics 98, 627–642, April 7, 2and genetically unrelated normal donors. Immunofluores-
cence staining of TTD379BE’s cells confirmed reduced
level of TFIIEb protein compared to normal control cells
(Figure 3C). In addition, the reduction of both TFIIEa
and TFIIEb did not affect the nuclear distribution after
localized UV irradiation, providing additional evidence
that TFIIE is not involved in NER (Figure 3D). Overall,
these findings point to the involvement of TFIIE in the
pathological phenotype of affected children TTD28PV
and TTD379BE.
Mutations in GTF2E2 Are Associated with a Non-
photosensitive Form of TTD
In TTD379BE, whole-exome sequencing detected a
homozygous, non-synonymous missense mutation in
GTF2E2 (c.448G>C [p.Ala150Pro]; GenBank: NM_
002095.4), which encodes the 34 kDa TFIIEb protein.
Sanger sequencing (Figure 4A) and restriction fragment
length polymorphism testing (Figure S3) confirmed the
mutation and identified heterozygous mutations in
both parents but not in the unaffected brother. In
TTD28PV, targeted Sanger sequencing of PCR-amplified
cDNA of both TFIIE subunits was performed. No muta-
tions were detected in GTF2E1 whereas GTF2E2 analysis
revealed the presence of a homozygous, non-synony-
mous missense mutation (c.559G>T [p.Asp187Tyr])
(Figure 4B). Sequencing of the relevant genomic DNA
region demonstrated that TTD28PV’s parents were het-
erozygous (Figure 4B). The healthy siblings were either
heterozygous (sister) or did not carry the variant (brother)
(Figure 4B). The c.448G>C and c.559G>T changes
were not reported in dbSNP, and the affected amino
acids were conserved across species (Figure 4C). The
two variants obtained high pathogenicity scores in
three independent prediction algorithms—PolyPhen2,28016
Figure 2. Normal DNA Repair in Pri-
mary Fibroblasts from TTD379BE and
TTD28PV
(A) Post-UV cell survival in normal,
TTD379BE, TTD28PV, XP29BE (XP/XP-D),
and TTD351BE (TTD/XP-D) cells. Bars indi-
cate SEM.
(B) Post-UVhost cell reactivation innormal,
TTD379BE, TTD28PV, and XP29BE (XP/
XP-D) fibroblasts. Cells were transfected
with an UV-C-irradiated (1,000 J/m2) lu-
ciferase reporter vector and incubated for
48 hr. Repair of the plasmid is expressed
as induced light units of active lucif-
erase compared to a non-irradiated lu-
ciferase plasmid. Two experiments each
in triplicate were performed. Bars indi-
cate SEM.
(C and D) Repair of 6-4 photoproducts
(6-4PP) (C) and cyclobutane pyrimidine
dimers (CPD) (D) measured by immu-
nofluorescence in normal, TTD379BE,
TTD28PV, and XP29BE (XP/XP-D) fibro-
blasts. Cells were irradiated with 100 J/m2
UVC through a filter with 5 mm pores to
generate localized DNA damage. 100
nuclei were scored. Bars indicate SEM.
(E) Immunofluorescence analysis of NER
proteins in normal (incubated with 1 mm
beads, yellow arrows) and TTD379BE or
TTD28PV (incubated with 2 mm beads,
red arrows) cells loaded on the same cover-
slip and irradiated with 100 J/m2 UVC
through a filter with 5 mm pores to
generate localized DNA damage. Post-UV
localization of XPD protein to the
damaged sites is not detected () in
XP29BE (XP/XP-D) cells but is present
(þ) at normal levels in TTD28PV and
TTD379BE cells.SIFT,27 and MutationTaster39 (Table S3)—strongly sug-
gesting a disease-causing effect. The altered amino acids
are 14 A˚ apart on different surfaces of the wing helix 2
(WH2) region of the TFIIEb protein (Figure 4D). The
p.Ala150Pro change would be expected to destabilize
the long alpha helix and cause it to bend or locally un-
fold (W. Yang, personal communication).
After identification of the mutations in GTF2E2 in the
affected children TTD379BE and TTD28PV, we performed
Sanger sequencing of GTF2E2 and GTF2E1 in 41 addi-
tional individuals with clinically suspected TTD where
NER defects or TTDN1 mutations had not been identified
(15 individuals from 13 families tested in Italy, 6 individ-
uals from 4 families tested at the NIH, and 20 individuals
tested in the UK). No mutations were identified in either
GTF2E2 or GTF2E1, suggesting that additional genes are
involved in TTD. In our combined cohort of 125 TTD-
affected case subjects (48 from Italy, 36 from NIH, and
41 from UK), mutations in GTF2E2 accounted for about
2% of the cases.The AmGTF2E2 Mutations Affect the Stability of TFIIE
Complex
In TTD28PV and TTD379BE, the transcript levels of
GTF2E2 and GTF2E1 were in the normal range (Figures
5A and 5B). This result indicates that the mutations in
GTF2E2 did not affect the transcription of the gene but
impacted TFIIEb stability because the level of TFIIEb pro-
tein was reduced (Figure 3). This, in turn, affects the stabil-
ity of the entire TFIIE complex as shown by the equally
reduced level of both TFIIE subunits in TTD28PV and
TTD379BE cells (Figure 3A).
The quantitative relationship between the a and b sub-
units of TFIIE was investigated by silencing of GTF2E2
(via RNAi) in normal skin fibroblasts. We observed that
GTF2E2 silencing resulted in reduced mRNA and protein
levels of TFIIEb (Figures 5C and 5D). The reduced TFIIEb
amount did not affect the mRNA level of GTF2E1 but
instead caused a striking reduction (about 50%) of TFIIEa
protein, suggesting that a stable complex between both
TFIIE subunits was required to maintain normal levels oferican Journal of Human Genetics 98, 627–642, April 7, 2016 633
Figure 3. Reduced Steady-State Levels of TFIIE and Normal Levels of Other General Transcription Factors in Primary Fibroblasts from
Affected Individuals TTD379BE and TTD28PV
(A) Immunoblot analysis of whole-cell lysates with antibodies against the a and b subunits of TFIIE, TBP, TFIIB, the CDK7, p44, p62, and
XPD subunits of TFIIH, and TTDN1. g-tubulin was used as loading control. The amount of each protein was first expressed as the mean
value of the levels observed in the three increasing concentrations of the cell lysate and normalized to the g-tubulin content. The protein
levels in both TTD cell strains were then expressed as percentages of the corresponding values in the normal (C3PV) cells. The reported
values are the means of at least two independent experiments. Bars indicate the SE.
(B) Anti-TFIIEa and anti-TFIIEb immunoblot analysis of whole-cell lysates from lymphoblastoid cells of TTD28PV and her unaffected
mother, father, and sister. The amount of the analyzed proteins was determined as described in (A); the levels of TFIIEa and TFIIEb
are expressed as percentages of the corresponding values in the normal C6PV lymphoblasts. The mean levels of two independent exper-
iments are reported. Bars indicate the SE.
(C) Reduced immunofluorescence of TFIIEb protein in TTD379BE cells (incubated with 2 mm beads, red arrow) compared to normal cells
(incubated with 1 mm beads, yellow arrows).
(D) Immunofluorescence detection of reduced levels of TFIIEb and TFIIEa in TTD28PV and TTD379BE cells. TTD and normal cells were
labeled as in Figure 2C and irradiated with 100 J/m2 UVC through a filter with 5 mm pores to generate localized DNA damage. The TFIIE
proteins were reduced in the TTD cells. There was no localization of TFIIE proteins at the site of localized DNA damage in the TTD or
normal cells.TFIIEa and TFIIEb. No reduction was observed in the
cellular concentration of TFIIH subunits or of TTDN1
with GTF2E2 RNAi confirming that quantitative alter-
ations of TFIIEb specifically interferes with the stability of
the whole TFIIE complex without affecting the cellular
concentration of the other factors involved in TTD
pathogenesis.
GTF2E2 Mutations Interfere with the
Phosphorylation of TFIIEa
Two distinct bands can be resolved for TFIIEa by immuno-
blotting of primary fibroblast lysates prepared by directly
scraping cells in Laemmli buffer (Figure 6A). In normal fi-634 The American Journal of Human Genetics 98, 627–642, April 7, 2broblasts, the upper band of the doublet represents 75%
(SE 51.7) of the total TFIIEa amount. In GTF2E2 mutant
cells from affected children TTD28PV and TTD379BE, no
significant variations were observed in the level of the
lower band whereas the upper band was drastically
reduced (29% compared to normal, p < 0.0005), thus ac-
counting for the reduced amount of total TFIIEa (50%
compared to normal, p < 0.0005).
Because it was previously demonstrated by in vitro
kinase assays that TFIIEa can be phosphorylated by
TFIIH kinase activity,20 we investigated whether the
different electrophoretic mobility of the two TFIIEa
bands is the result of different phosphorylation states. By016
Figure 4. Identification of Missense Mutations in GTF2E2 in Affected Children TTD379BE and TTD28PV
(A) Electropherograms showing the change identified in GTF2E2 in TTD379BE and his unaffected father and mother but not in the
unaffected brother.
(B) Electropherograms showing the change identified in GTF2E2 (GenBank: NM_002095.4, NC_000008.10) in TTD28PVand unaffected
father, mother, and sister but not in the unaffected brother. For cDNA numbering, þ1 corresponds to the A of the ATG translation initi-
ation codon in the reference sequence.
(C) Conservation of amino acids Ala150 and Asp187 in multiple protein sequence alignment of TFIIEb regions in 13 species (from
HomoloGene: 37573).
(D) Structural location of amino acid changes in TFIIEb protein resulting fromGTF2E2 homozygous missensemutations in TTD-affected
individuals. Each winged-helix (WH) domain consists of three helices (cylinders) and a beta-hairpin (two strands). The protein is colored
from N to C terminus from blue (WH1 domain), blue-green (WH2 domain), to red (C terminus). The altered amino acids (p.Ala150Pro
and p.Asp187Tyr) are 14 A˚ apart on different surfaces of wing helix 2 (WH2) region of the TFIIEb protein. The p.Ala150Pro change will
destabilize the long alpha helix and cause it to bend or locally unfold (W. Yang, personal communication).a phosphoprotein-enrichment assay, we observed that the
upper band of TFIIEa was exclusively present in the phos-
pho-protein-enriched fraction of normal C3PV fibroblasts
whereas the lower band was more abundant in the
unphosphorylated fraction (Figure 6B). We next immuno-
precipitated the TFIIEa protein from a total cell lysate and
immunoblotted with antibodies specific for phosphory-
lated serine, threonine, or tyrosine residues. As shown
in Figure 6C, the upper band was recognized only by the
anti-serine antibody, thus demonstrating that TFIIEa
is serine phosphorylated. Unfortunately, we were not
able to assess the phosphorylation status of the lower
band in these experiments, because it ran with the same
mobility as a non-specific band (indicated by asterisk in
Figure 6C).
To better clarify the relationship between the upper and
lower bands of TFIIEa, we transiently transfected C3PV fi-
broblasts with a DNA plasmid encoding the recombinant
TFIIEa protein tagged with Flag epitope (TFIIEaFlag). In
the whole-cell extract of transfected cells (Figure 6D,The Aminput), the TFIIEa antibody recognized three bands: two
corresponding to the endogenous lower and upper band,
respectively, and the third one with a molecular weight
(MW) higher than that of the endogenous upper band. Af-
ter immunoprecipitation with anti-TFIIEa antibodies, a
clear signal was detected at the MW corresponding to the
endogenous TFIIEa upper form. Immunoprecipitation
with anti-Flag antibodies followed by anti-TFIIEa immuno-
blot revealed two protein bands, one corresponding to the
form with the highest MW and one with the same size as
the endogenous TFIIEa upper form. Thus, the Flag epitope
imposed an electrophoretic up-shift to both the upper and
lower bands, the latter with an electrophoretic mobility
similar to the endogenous TFIIEa upper form.
Next, we incubated the whole extract of TFIIEaFlag-ex-
pressing fibroblasts with calf intestinal alkaline phos-
phatase for 30 and 60 min and the efficiency of the
phosphatase treatment was demonstrated by the shift
from the IIo to the IIa form of RNA pol (Figure 6E). A reduc-
tion in the amount of the TFIIEaFlag upper form waserican Journal of Human Genetics 98, 627–642, April 7, 2016 635
Figure 5. GTF2E2 Mutations Do Not
Affect the Cellular Amount of GTF2E2
and GTF2E1 Transcripts but Interfere
with the Stability of TFIIE Complex
(A) GTF2E2 (black columns) and GTF2E1
(gray columns) transcript levels in primary
fibroblasts from the healthy donor
C16354BE, affected individual TTD379BE,
his father, and affected individual
XP29BE (XP/XP-D). Transcript levels were
normalized to GAPDH levels and then ex-
pressed as percentages of the correspond-
ing value in the healthy donor analyzed
in parallel. The reported values are the
means of two independent experiments,
each done in triplicate. Bars indicate
the SE.
(B) GTF2E2 (black columns) and GTF2E1
(gray columns) transcript levels in primary
fibroblasts from healthy donors C3PV,
C1609RM, and C377RM and affected indi-
vidual TTD28PV. Transcript levels were
expressed as in (A). The reported values
are the means of two independent experi-
ments, each done in triplicate. Bars indi-
cate the SE.
(C) GTF2E2 and GTF2E1 transcript levels in C3PV primary fibroblasts 12, 24, and 48 hr after transfection with GTF2E2 or control siRNA.
GTF2E2 (black columns) and GTF2E1 (gray columns) transcript levels were normalized to GAPDH and expressed as percentages of the
corresponding value in untransfected C3PV cells.
(D) Immunoblot analysis of whole-cell lysates fromC3PV primary fibroblasts 12, 24, and 48 hr after transfection withGTF2E2 or control
siRNA. Antibodies against the a and b subunits of TFIIE, the CDK7, p62, and XPD subunits of TFIIH, TTDN1, and g-tubulin (loading
control) were used. The levels of the analyzed proteins were normalized to g-tubulin and expressed as percentages of the corresponding
values in untransfected C3PV cells.paralleled by the appearance of an extra band with a
slightly lower MW (black and white arrowheads, respec-
tively), confirming the phosphorylation of the upper
band. However, the mobility of the dephosphorylated
form of the upper band of the FLAG-tagged protein was
still slower than that of the lower band of FLAG-tagged
protein seen in Figure 6D, suggesting that the dephos-
phorylated TFIIEaFlag form has an additional post-transla-
tional modification.
To verify whether this holds true also for the endogenous
TFIIEa, we incubated the whole lysate of normal C3PV fi-
broblasts with calf intestinal alkaline phosphatase for
increasing time periods in the absence or presence of phos-
phatase inhibitors. Already at the shortest incubation time
(5 min), the size of the upper band was slightly reduced
(shift from the black to the white arrowheads) and per-
sisted over time (Figures 6F and S4) but did not approach
that of the lower band. The presence of the phosphatase
inhibitors prevented the TFIIEa dephosphorylation, as
demonstrated by the lack of any mobility downshift of
the TFIIEa upper form.
To evaluate the contribution of the CDK7 serine/threo-
nine kinase to the in vivo phosphorylation of TFIIEa, the
CDK7 expression in normal C3PV fibroblasts was investi-
gated via CDK7 RNAi. A substantial decrease of the CDK7
mRNA level (to 6%–8% of normal) as well as a 50%–60%
reduction of the CDK7 protein amount was observed after
silencing. This was followed by a decrease in the amount of
the p44, p62, and XPD subunits of TFIIH complex but not636 The American Journal of Human Genetics 98, 627–642, April 7, 2of the transcription factor TBP (Figure S5). This result dem-
onstrates that reduction in CDK7 can influence the cellular
concentrations of other proteins in the TFIIH complex. In
addition, CDK7 siRNA altered the phosphorylation status
of TFIIEa as shown by the small but reproducible and sta-
tistically significant decrease (p < 0.05) in the amount of
the phosphorylated TFIIEa (upper band) 72–96 hr after
siRNA transfection (Figures 6G and S5). Because we were
unable to reduce the CDK7 protein concentration to less
than 50%, we cannot make a definitive conclusion, but
our findings are consistent with the in vitro data demon-
strating that TFIIEa is a substrate of the CDK7 kinase
activity of TFIIH. Moreover, a statistically significant reduc-
tion (p < 0.05) in the amount of the TFIIEb subunit was
also observed in CDK7-silenced fibroblasts, suggesting a
possible interaction of TFIIEb with the phosphorylated
form of TFIIEa.
Alterations in the Phosphorylation Status of TFIIEa
Are Common in TTD Cells
Cells from photosensitive individuals with TTD typically
have a reduced content of the entire TFIIH complex result-
ing from mutations in genes encoding the XPD, XPB, or
TTDA protein subunits of TFIIH (Table S1).6,29,30,40
Because the kinase activity of TFIIH phosphorylates
TFIIEa, we asked whether the TFIIH alterations found in
the photosensitive TTD-affected case subjects affect TFIIE.
We performed immunoblot analysis of fibroblast lysates
from six TTD-affected individuals with alterations in the016
Figure 6. Reduced Amount of Phosphorylated TFIIEa in Primary Fibroblasts of Affected Individuals TTD379BE and TTD28PV and in
Normal C3PV Fibroblasts after CDK7 Silencing
(A) Immunoblot analysis of lysates obtained by directly scraping normal (C3PV and TTD379BE parents) and TTD (TTD28PV and
TTD379BE) cells in Laemmli buffer. The levels of the upper (gray) and lower (white) forms of TFIIEa and of TFIIEb (black) were normal-
ized to g-tubulin and expressed as percentage of the corresponding values in C3PV cells. The reported values are themeans of at least two
independent experiments. Bars indicate the SE. The statistically significant reduction of TFIIEa (***p < 0.0005; Student’s t test) refers to
the upper band, no significant difference was observed for the lower band.
(B) Immunoblot analysis of TFIIEa and TFIIEb in unphosphorylated (NP) and phosphorylated (P) protein-enriched fractions of cell ly-
sates from normal C3PV fibroblasts. TBP and RNA pol IIo-Ser5 were used as positive controls of the NP and P fractions, respectively.
(C) Immunoprecipitation of TFIIEa or IgG from HeLa total cell lysates and identification of the phosphorylated residue. The TFIIEa or
IgG immunoprecipitates (IP) were analyzed by immunoblotting using phosphoaminoacid-specific antibodies. The positive controls (crl)
are made of proteins phosphorylated on serine (ser), threonine (thr), or tyrosine (tyr), provided by the kit. Asterisks (*) indicate non-spe-
cific bands.
(D) Immunoprecipitation of TFIIEa, TFIIEaFlag, or IgG from cell lysates of C3PV normal fibroblasts transfected with the pMP2-TFIIEaFlag
DNA plasmid expressing the TFIIEaFlag recombinant protein. The immunoprecipitates (IP) were analyzed by immunoblotting using anti-
TFIIEa antibodies. Asterisks (*) indicate the upper and lower bands of TFIIEaFlag.
(E) Immunoblot analysis of TFIIEa after phosphatase treatment of the cell lysate from C3PV fibroblasts transfected with the pMP2-
TFIIEaFlag DNA plasmid. The lysate was incubated at 37C with 3 U/mL of calf intestinal phosphatase for the indicated time points.
Arrowheads indicate the phosphorylated (black) and dephosphorylated (white) upper form of TFIIEaFlag. As positive control, the phos-
phorylation status of RNA Pol IIo over the unphosphorylated RNA pol IIa was investigated in parallel. g-tubulin is the loading control.
(F) Immunoblot analysis of TFIIEa in the cell lysate from normal C3PV fibroblasts after phosphatase treatment. The lysate was incubated
at 37Cwith 3 U/mL of calf intestinal phosphatase in the presence or absence of phosphatase inhibitors (PhosSTOP 13) for the indicated
time points. Arrowheads indicate the phosphorylated (black) and dephosphorylated (white) upper form of TFIIEa. As positive control,
the phosphorylation status of RNA Pol IIo over the unphosphorylated RNA pol IIa was investigated in parallel. g-tubulin is the loading
control.
(G) Immunoblot analysis of whole-cell lysates from C3PV fibroblasts 72 hr after transfection with CDK7 siRNA or control siRNA. The
levels of CDK7 and the upper and lower forms of TFIIEa and TFIIEb were normalized to the g-tubulin content and expressed as percent-
age of the corresponding value in untransfected C3PV cells. The reported values are the mean of two independent experiments. Bars
indicate the SE. The statistically significant reduction of TFIIEa (*p < 0.05; **p < 0.005; Student’s t test) refers to the upper band; no sig-
nificant difference is observed for the lower band.XPD subunit of TFIIH, the most common form of TTD. We
found normal cellular amounts of total TFIIEa (100%–
117% of that in C3PV) in non-proliferating and prolifer-
ating cells (Figures 7 and S6) in agreement with our
previous observations.29,30 Similar to the healthy donors,
the amount of the upper form of TFIIEa ranged from
70% to 80% of the total TFIIEa in proliferating (sub-The Amconfluent) TTD fibroblasts (Figure S6). In contrast, in
non-proliferating (confluent) TTD cells, the level of the up-
per band was reduced to 40%–60% of the total TFIIEawith
a parallel increase in the level of the lower band (Figure 7).
In addition, a slight but significant decrease (p< 0.0005) in
the cellular content of TFIIEb subunit was observed,
thus resembling the situation previously observed inerican Journal of Human Genetics 98, 627–642, April 7, 2016 637
Figure 7. TFIIEa Phosphorylation Is
Impaired in Non-proliferating TTD/XP-D
Primary Fibroblasts
Immunoblot analysis of lysates obtained
by directly scraping four normal (C3PV,
C1609RM, C377RM, and C16354BE), six
TTD/XP-D (TTD8PV, TTD11PV, TTD12PV,
TTD22PV, TTD23PV, and TTD24PV), and
six XP/XP-D (XP16PV, XP29BE, XP17BE,
XP34BE, XP35BE, and XP17PV) fibroblast
strains in Laemmli buffer. The levels of
the upper (gray) and lower (white) forms
of TFIIEa and of TFIIEb (black) were
normalized to g-tubulin and expressed as
percentage of the corresponding values in
C3PV cells. The reported values are the
means of at least two independent ex-
periments. Bars indicate the SE (***p <
0.0005; ns, not statistically significant; Stu-
dent’s t test).CDK7-silenced cells (Figure 6G). In contrast, normal levels
of the upper and lower bands of TFIIEa were observed in
cells from six XP-affected individuals with mutations in
ERCC2 (XPD) in proliferating and non-proliferating cells
(Figures 7 and S6). Overall, these findings demonstrate
that in non-proliferating, confluent cells, XPD alterations
associated with the photosensitive TTD phenotype, but
not those resulting in XP, impair the phosphorylation of
TFIIEa. Because these differences in TFIIEa phosphoryla-
tion are present in cells from individuals with TTD
with mutations in ERCC2 (Figure 7) and in GTF2E2
(Figure 6A), alterations in the phosphorylation status of
TFIIEa appear to be a specific feature of TTD cells.Discussion
Several general transcription factors assemble into a pre-
initiation complex (PIC) to ensure accurate RNA pol II
loading at the transcription start site. Among them, the
basal transcription factor IIE (TFIIE) is essential for PIC
assembly and stabilization.17 Direct interaction of TFIIE
(mainly through its TFIIEa subunit) to TFIIH is required
for both PIC formation and the transition from initiation
to elongation.41 TFIIEa interacts with XPB, p52, and p62
of TFIIH as well as with other transcription factors TFIIB,
TFIIFb, and TBP.42,43 On a supercoiled DNA template, TFIIE
can melt the promoter independently of TFIIH, but on
linearized template both TFIIE and TFIIH are necessary
for the transition activity from the initiation to elonga-
tion.44
Both GTF2E2 homozygous mutations present in the
children with TTD reported in this paper alter the WH2
domain (residues 142–207) of the TFIIE beta subunit
(TFIIEb) (Figure 4D). p.Ala150Pro lies within a leucine
repeat motif and p.Asp187Tyr within a s3 region that is
similar to the bacterial s factor subdomain 3.45 TFIIEb
binds to the WH domain of TFIIEa via its bHLH domain
(basic region-helix-loop-helix motif, residues 193–240).
The bHLH domain of TFIIEb also binds to RNA pol II as638 The American Journal of Human Genetics 98, 627–642, April 7, 2well as to ssDNA, TFIIF, and TFIIB.46 TFIIEb also binds
XPB.47 The p.Ala150Pro change will destabilize the long
alpha helix and cause it to bend or locally unfold
(W. Yang, personal communication).
In confluent fibroblast cultures from all individuals with
TTD studied here (but not from the individuals with XP
with mutations in ERCC2), we observed reduced amount
of the upper form of TFIIEa (Table 2 and Figures 6A, 7,
and S1). This is in line with the observation that, being
compatible with life, the transcriptional failure in TTD oc-
curs only under certain circumstances and/or in specific
cellular compartments.36,48–52 In particular, high cell den-
sity is known to regulate the expression of specific target
genes by triggering a cascade of phosphorylation-mediated
pathways that ultimately result in more efficient transcrip-
tion of specific genes (Orioli et al.9 and references therein).
Intriguingly, the reduced level of serine-phosphorylated
TFIIEa is seen with GTF2E2 mutations leading to reduced
TFIIE protein levels, as well as with ERCC2 mutations
with normal TFIIE protein levels (Figures 6 and 7).
In vitro studies have shown that the serine/threonine ki-
nase CDK7, which is part of the CAK complex of TFIIH,
can phosphorylate TFIIEa20 as well as TFIIEb.53 In addi-
tion, TFIIE itself influences TFIIH activity by positively
regulating CDK7 and XPD subunits.54 Overall, our find-
ings support the causal link between CDK7 and TFIIEa
phosphorylation (Figure 6G) and, therefore, the in vivo
relevance of the crosstalk between TFIIE and TFIIH in tran-
scription. In the two TTD-affected children withmutations
in GTF2E2, several different scenarios could explain the
reduced TFIIEa phosphorylation. The GTF2E2 mutations
could affect the stability of the TFIIE complex, leading to
degradation of both TFIIEa and TFIIEb, which results in
less TFIIEa substrate available for CDK7 phosphorylation
and in turn to much less phosphorylated TFIIEa compared
to normal cells. Additionally, reduced levels of total TFIIE
could affect CDK7 function resulting in reduced TFIIEa
phosphorylation. In the TTD-affected individuals with
mutations in ERCC2, decreased TFIIEa phosphorylation
could be a consequence of altered TFIIH integrity. As016
revealed by solution of the crystal structure of archaeal
XPD,55,56 the mutations found in TTD are predicted to
decrease the stability of the XPD protein framework, ac-
cording with the reduced level of the TFIIH content typi-
cally present in TTD cells.57 Furthermore, all the ERCC2
mutations found in individuals with TTD diminish the
basal transcription activity of TFIIH.8
Our results suggest that TFIIEb pathological changes
could lead to altered RNA pol II-driven transcription via de-
regulated phosphorylation events, which might include
TFIIEa phosphorylation seen in TTD-affected individuals
with ERCC2 (XPD) mutations (Tables 2 and S1 and
Figure S1). Reduced TFIIEa phosphorylation (Figures 6A
and 7) could impair TFIIE function, which would affect
the correct positioning of TFIIF, TFIIH, and RNA pol II at
the PIC. Moreover, CDK7 controls the disengagement of
TFIIE and recruits DRB sensitivity inducing factor (DSIF),
thus allowing the pausing of RNA pol II to ensure gene-spe-
cific regulation and the recruitment of RNA-processing en-
zymes before elongation.53 Our data suggest that reduced
phosphorylation of TFIIEa by CDK7 might affect TFIIE
function on transcription initiation and elongation.
Individuals with (different) alterations in the XPD sub-
unit of TFIIH might have the clinical phenotype of XP
with markedly increased cancer risk on sunlight-exposed
tissues or TTD with normal cancer risk and developmental
abnormalities (Table 1 and Figure S1). Cultured cells from
these individuals with XP or with TTD have impaired
post-UV DNA repair and additionally have defective tran-
scription.7,8,58 One explanation for the difference in
phenotype is that the XP phenotype results from a pre-
dominance of the DNA repair defect whereas TTD is a
consequence of a primary transcription abnormality.
Studies in cells from TTD-affected individuals and mouse
models support the relevance of transcriptional alterations
to the TTD clinical outcome (reviewed in Stefanini et al.6).
Besides defects in the basal transcription activity of TFIIH,8
several lines of evidence have highlighted gene expression
deregulations in TTD3,38,49,52,59–62 that result from altered
signaling events, including the TFIIH-dependent activa-
tion of nuclear receptors as well as the TFIIH-mediated acti-
vation or displacement from the chromatin of specific
transcription regulators.8–11,37,51 The mutations leading
to the TTD phenotype appear to alter the overall TFIIH
structure, thus impairing TFIIH-dependent transcription.
The individuals with TTD we report have mutations in
the basal transcription factor GTF2E2 with normal DNA
repair (Table 2 and Figure S1). We also found decreased
phosphorylation of TFIIEa in TTD cells with mutations
in GTF2E2 or ERCC2 (which encodes the TFIIH subunit
XPD) but not in XP cells with ERCC2 mutations. Collec-
tively, our study underlines the role of TFIIE in transcrip-
tion and its distinction from NER. The individuals with
TTD with mutations in GTF2E2 highlight the importance
of the direct interaction between TFIIH and TFIIE in the
transcription process leading to a TTD clinical phenotype.
Our results thus provide a link between the photosensitiveThe Amand non-photosensitive forms of TTD and support the
notion that the TTD clinical outcome is due to transcrip-
tional defects, which in turn represent the major determi-
nant distinguishing TTD from XP.Supplemental Data
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